14 completed, 4 recruiting, 2 not yet recruiting, 1 terminated. 22 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 14, Recruiting 4, Not yet recruiting 2, Terminated 1, Unknown 1 |
| Phase 2 | 7 | Completed 5, Recruiting 1, Unknown 1 |
Follow Chipscreen Biosciences, Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets Chiglitazar/Metformin extended-release tablets under fasting conditions, Chiglitazar/Metformin extended-release tablets after a high-fat meal, multiple-dose of Chiglitazar/Metformin extended-release tablets - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Not yet recruiting | Chipscreen Biosciences, Ltd. | 28 | 2026-10-08 | 2026-04-06 |
| A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma CS08399 - Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Chipscreen Biosciences, Ltd. | 186 | 2026-06-01 | 2026-05-13 |
| A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis CS32582 capsule（low dose） or matched placebo, CS32582 capsule（high dose） or matched placebo, CS32582 capsule（low dose） - Plaque Psoriasis | Phase 1 / Phase 2 | Recruiting | Chipscreen Biosciences, Ltd. | 220 | 2025-09-08 | 2025-09-10 |
| Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors CS231295 - Neoplasms, Glioblastoma, Adult | Phase 1 | Recruiting | Chipscreen Biosciences, Ltd. | 102 | 2025-05-21 | 2025-05-25 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules CS32582 capsule, Placebo capsule - Healthy | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 112 | 2024-03-28 | 2024-12-03 |
| A Study of CS23546 in Subjects With Advanced Tumors CS23546 - Advanced Tumors | Phase 1 | Recruiting | Chipscreen Biosciences, Ltd. | 156 | 2024-03-27 | 2026-04-06 |
| A Study of NWY001 in Subjects With Advanced Solid Tumors NWY001 - Advanced Solid Tumor | Phase 1 | Recruiting | Chipscreen Biosciences, Ltd. | 196 | 2024-01-05 | 2024-07-16 |
| A Clinical Trial of CS12192 in Healthy Subjects CS12192 capsule, Placebo capsule - Healthy | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 108 | 2023-07-20 | 2024-02-07 |
| Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects. Chiglitazar, Empagliflozin, Atorvastatin - T2DM | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 48 | 2023-02-17 | 2023-06-15 |
| Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function Chiglitazar - Hepatic Impairment | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 24 | 2022-12-03 | 2024-05-28 |
| Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function Chiglitazar - Renal Impairment | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 24 | 2022-11-20 | 2024-05-28 |
| Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. Chiauranib - Small Cell Lung Cancer, Advanced Solid Malignant Tumor | Phase 1 / Phase 2 | Unknown | Chipscreen Biosciences, Ltd. | 36 | 2022-08-26 | 2024-07-16 |
| A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer AK104 IV infusion；Chiauranib oral - SCLC,Extensive Stage | Phase 1 / Phase 2 | Completed | Akeso | 36 | 2022-08-26 | 2025-03-12 |
| Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers Chiauranib - Healthy Volunteers | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 16 | 2022-06-02 | 2023-02-09 |
| Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Chiauranib, Chidamide - Non-hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | Chipscreen Biosciences, Ltd. | 9 | 2019-07-11 | 2022-03-09 |
| Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma Chiauranib - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Chipscreen Biosciences, Ltd. | 27 | 2018-04-28 | 2021-06-18 |
| Phase Ib Study of Chiauranib in Patients With Ovarian Cancer Chiauranib - Ovarian Cancer | Phase 1 / Phase 2 | Completed | Chipscreen Biosciences, Ltd. | 25 | 2017-12-15 | 2020-01-18 |
| Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer Chiauranib - Small Cell Lung Cancer | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 48 | 2017-11-09 | 2023-08-30 |
| Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma Chiauranib - Non-Hodgkin's Lymphoma | Phase 1 | Terminated | Chipscreen Biosciences, Ltd. | 5 | 2017-05-09 | 2019-07-24 |
| Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients Chidamide, cyclophosphamide, adriacin - Peripheral T-cell Lymphoma | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 30 | 2016-08-11 | 2019-07-24 |
Showing 20 of 22. Sign in to see all of them.
Small Cell Lung Carcinoma (3) · Lymphoma, Non-Hodgkin (2) · Recurrence (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Diabetes Mellitus, Type 2 (1) · Glioblastoma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Renal Insufficiency (1)
chiauranib (8) · chiglitazar (4) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (3) · Atorvastatin (1) · Cyclophosphamide (1) · Doxorubicin (1) · HBI-8000 (1) · Prednisone (1) · Valsartan (1) · Vincristine (1) · empagliflozin (1)
China (20) · Australia (1) · United States (1)
LiYan Miao (3) · Cabilia Pichardo, MD (1) · Hongrong Xu (1) · Huiqiang Huang, Ph.D. (1) · Ruihua Xu, Ph.D. (1) · Wenbin Li, M.D. (1) · Ying Cheng, M.D. (1) · Ying Cheng, Professor (1) · Yongtao Sun, M.D., Ph.D. (1) · Yuankai Shi (1) · Yuankai Shi, MD (1)